Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.

廣州白雲山醫藥集團股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 00874)

NOTICE OF THE SECOND EXTRAORDINARY GENERAL MEETING IN 2026

IMPORTANT NOTICE

- Date and time of the second extraordinary general meeting in 2026 (the "**EGM**"): 1 December 2026 (Tuesday) at 10:00 a.m.

- Venue of the EGM: Conference Room of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the "**Company**"), No. 45 Sha Mian North Street, Liwan District, Guangzhou City, Guangdong Province, the People's Republic of China (the "**PRC**")

I. INFORMATION REGARDING THE CONVENING OF THE EGM

1. Resolution to Convene the EGM

The resolution to convene the EGM was considered and approved at the sixth meeting of the tenth session of the board of directors (the "**Board**") of the Company.

2. Date and Time of the EGM

The EGM will be held on 1 December 2026 (Tuesday) at 10:00 a.m.

3. Venue of the EGM

The EGM will be held at the Conference Room of the Company, located at No. 45 Sha Mian North Street, Liwan District, Guangzhou City, Guangdong Province, the PRC.

4. Convener of the Meeting

The convener of the EGM is the Board.

II. MATTERS TO BE CONSIDERED AT THE EGM

To consider and, if thought fit, to pass the following as an ordinary resolution by poll (non-cumulative voting):

Resolution on Guangzhou Pharmaceuticals Company Limited's Introduction of Strategic Investors through Public Listing and Private Placement of Shares

Specifically, it is proposed that:

(a) the proposal for Guangzhou Pharmaceuticals Company Limited ("**GP Corp.**") to introduce strategic investors through public listing and implement a private placement of shares (the "**Proposed Capital Increase**") and the proposed mandate as set out in the Company's circular dated 15 November 2026 (the "**Circular**") be approved, including the upper limits on the number of shares to be issued and the amount to be raised, the minimum issue price and pricing mechanism, the eligibility criteria and selection arrangements for investors, the number of investors and the maximum aggregate shareholding percentage for a single investor, investors under common control and persons acting in concert with it, the Company's minimum shareholding percentage upon completion of the Proposed Capital Increase, the cash subscription method, the use of proceeds and the principal terms of the template share subscription agreement, in each case as set out in the Circular, provided that GP Corp. shall remain a subsidiary of the Company upon completion of the Proposed Capital Increase;

(b) the management of the Company be authorised, within the scope of the proposal and mandate approved above and based on the results of the public listing and selection process, to determine the final investors, issue price, number of shares to be issued and subscription amounts, and to handle matters necessary to implement the Proposed Capital Increase. The mandate shall be valid for twelve months from the date on which this resolution is approved by the shareholders;

(c) within the scope and validity period of the mandate above, the management of the Company be authorised to negotiate and finalise the implementation arrangements, execute and submit documents required of the Company, complete filing and registration procedures, respond to comments from the relevant regulatory authorities and property rights exchange, lawfully complete the procedures required of the Company as a shareholder of GP Corp., and take such other actions as are necessary or appropriate to implement the approved proposal. The management of the Company may also make non-material amendments, supplements or adjustments to the relevant documents and implementation arrangements in light of applicable laws and regulations, regulatory requirements, the results of the public listing and the circumstances of implementation, provided that these do not exceed the scope of the mandate approved by the shareholders or constitute a material variation of the approved transaction proposal or its principal terms;

(d) the mandate above shall not extend to increasing the approved upper limits on the number of shares to be issued or the amount to be raised, lowering the minimum issue price or the Company's minimum shareholding percentage upon completion of the Proposed Capital Increase, changing the requirement that GP Corp. shall remain a subsidiary of the Company upon completion of the Proposed Capital Increase, extending the validity period of the mandate, or waiving any approval required by law or under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Hong Kong Listing Rules**"). Any matter falling outside the scope of the mandate, any material variation of the approved transaction proposal or its principal terms, or any arrangement triggering additional requirements under Chapter 14 or Chapter 14A of the Hong Kong Listing Rules shall be subject to separate compliance with the applicable disclosure and approval procedures, including obtaining approval from the Company's shareholders or independent shareholders where applicable, and the requirement set out in the Circular to complete the relevant procedures before GP Corp. approves or enters into the relevant arrangements shall be observed; and

(e) the mandate above shall not replace any board, shareholders' meeting or other approval procedures that the Company or GP Corp. is separately required to complete under applicable laws and regulations, their respective articles of association and relevant regulatory requirements.

III. ATTENDEES TO THE EGM, BOOK CLOSURE PERIOD FOR HOLDERS OF H SHARES AND DELIVERY OF THE PROXY FORM

For the purpose of determining the identity of the shareholders of H shares of the Company who will be entitled to attend and vote at the EGM, the H Share register of members of the Company will be closed from Thursday, 26 November 2026 to Tuesday, 1 December 2026 (both days inclusive), during which period no transfer of H shares will be effected. In order to qualify to attend and vote at the EGM, all share transfer documents of H shares together with the relevant share certificates must be lodged with the share registrar of the Company in Hong Kong, namely Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong for share transfer registration no later than 4:30 p.m. on Wednesday, 25 November 2026. Shareholders of H shares whose names are recorded in the register of members of the Company on Tuesday, 1 December 2026 will be entitled to attend and vote at the EGM.

Any shareholder entitled to attend and vote at the EGM is entitled to appoint one or more proxies (whether or not they are shareholders) as his/her proxy to attend, speak and vote at the EGM on his/her behalf. To be valid, the proxy form, along with any notarially certified power of attorney and/or other documents of authorization (if any), must be delivered to the office of the Company's H share registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong, no later than 10:00 a.m. on Monday, 30 November 2026 (or at least 24 hours before the time appointed for any adjournment thereof). Completion and return of the proxy form will not preclude shareholders from attending and voting in person at the EGM.

The directors and senior management of the Company, as well as the lawyers of the Company, will be in attendance.

IV. OTHERS

1.	Address:	Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, 2nd Floor, No. 45 Sha Mian North Street, Liwan District, Guangzhou City, Guangdong Province, the PRC
	Postal code:	510130
	Contact:	Board Secretary Office
	Tel:	(8620) 6628 1216
	Email:	sec@gybys.com.cn
2.	Address of Computershare Hong Kong Investor Services Limited:	17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong (for submitting proxy forms) Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong (for submitting share transfer documents)

3. The EGM is expected to last for half a day. Shareholders attending the EGM shall be responsible for their own travelling and accommodation expenses.

4. Reporters attending the EGM should register in advance during the registration time for shareholders.

The Board of
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 15 November 2026

As at the date of this notice, the Board comprises: (i) Mr. Chen Jiehui, Mr. Yuan Cheng, Mr. Cheng Hongjin, Mr. Tang Heping, Ms. Liu Lan and Mr. Liu Hong as executive Directors; (ii)Mr. Huang Jiyuan as non-executive Director; and (iii) Mr. Wong Lung Tak Patrick, Ms. Sun Baoqing, Mr. Wu Xiangneng and Mr. Yang Yinbao as independent non-executive Directors.